Tuesday, 12.12.2006 -- Epigenomics AG (Frankfurt, Prime Standard: ECX) announced today that it successfully transferred its prostate cancer molecular classification test, based on the PITX2 biomarker, to the Affymetrix GeneChip™ platform. This step, a milestone towards completing product development and initiating pivotal studies, was accomplished only six months after concluding a strategic partnership with Affymetrix Inc. (NASDAQ: AFFX). As previously reported, this partnership provides Epigenomics with access to Affymetrix’s industry leading in vitro diagnostic microarray platform for commercialization of Epigenomics’ tissue based product portfolio. The concordance study demonstrated that the prototype real-time PCR assays used in the research phase could be transferred to the Affymetrix platform. An excellent 97.8% agreement between the methods was observed.
